Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

Medline Inc. (MDLN)

As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data

Report price $39.17 (close 2026-11-16); latest close $37.04 (2026-11-20), -5.4% since the report; figures re-marked at the latest close

Conclusion: AVOID

Conviction medium · base case -31% · downside -48% · upside +16%

The market is still paying 44.5x FY2025 net income and 21.8x TTM EBITDA for a distributor earning 6.4% ROIC on 25.7% gross margins, so the good news is already in the price. That is why the call is AVOID. The base case is $25.44 (-35.1%), P/E at 28.9x, the peer median P/E. The downside case is $19.08 (-51.3%), the base case's multiple on -25.0% earnings. The upside case is $43.09 (+10.0%), +10% earnings at today's P/E of 44.5x — the best case adds a tenth while the base and downside sit well below the $39.17 close. The call also runs against large tracked-fund positions: SurgoCap Partners LP has 7.5% of its book in the name, trimmed at the quarter end, though 13F holdings are as of the quarter end and filed up to 45 days later. With a quality score of 20/100, 6.4% ROIC and free cash flow margin of 6.2%, a 28.9x peer multiple — not 44.5x — is the fair anchor.

Key numbers

  • Share price: $37.04
  • Market cap: $48.72B
  • Latest financial period: TTM to Sep 26, 2026
  • Revenue (TTM): $30.68B
  • EV / EBITDA (TTM): 20.8x
  • P/E (FY Dec 2025): 42.1x
  • FCF yield: 3.9%
  • Price / book: 4.13x
  • Earnings-quality flags (FY Dec 2025): none flagged
  • EV / FCF (TTM): 30.4x
  • Revenue growth (latest fiscal year): +11.5%
  • ROIC (TTM): 6.4%

The 15 boxes

  1. ✓ 1. Long-form business notes

    Medline is a 1966-founded med-surg manufacturer-distributor with two segments, Medline Brand and Supply Chain Solutions, spanning about 335,000 products and tied together by multi-year Prime Vendor contracts. It monetizes product breadth, Medline Brand margin conversion, and supply-chain services, supported by a 70-site distribution network, owned trucks, and a large U.S. commercial team. From FY2023 to FY2025 revenue rose from $23.23B to $28.43B and operating income from $1.25B to $2.21B. TTM to Sep 26 2026 revenue was $30.68B, but TTM operating income was $1.74B, below FY2025.

  2. ✓ 2. Competitive advantage

    Medline's claimed advantage is structural rather than brand-led: it is both a manufacturer (about one-third of Medline Brand products in 30 plants, 24 in North America) and a distributor with 70 facilities and over 2,100 MedTrans trucks, and it argues rivals reliant on third-party distribution lack that vertical scale. The margin record does not yet prove pricing power: gross margin went ~25.3% (FY2023) to ~26.4% (FY2025) and back to ~25.7% (TTM to 2026-09-26), while operating margin fell to ~5.7% TTM from ~7.8% FY2025 even as revenue rose $2.25B. Advantage looks real in sourcing breadth and distribution density, but bargaining power sits largely with GPOs and large customers, and competition is explicitly on price against McKesson, Cardinal Health, Owens & Minor and Henry Schein.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 net sales rose 10.4% to $7,856M with organic sales up 10.5%, but GAAP net income fell 1.2% to $318M as gross margin compressed to 24.5% and SG&A rose; Adjusted EBITDA rose 11.8% to $960M. Nine-month net income fell 28.8% to $696M, including $316M of net Tracy fire losses, while net IEEPA tariff refund benefits were $324M. Management raised FY2026 organic sales growth guidance to 10.0%-10.5% and reaffirmed Adjusted EBITDA of $3.3B-$3.4B, and the board authorized a $1B buyback in October 2026. The 10-Q states no material changes to risk factors.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans